Glioblastomas are the most common primary brain tumor, but despite aggressive treatment, continue to be marked by a poor prognosis, with a median survival of 14.6 months for glioblastoma (GBM). 1, 2 These tumors at recurrence are particularly challenging given the lack of effective salvage therapy, with 6 month progression free survival (PFS-6) ranging from 3 -15% in patients with GBM. 3, 4 Angiogenesis in glioblastomas is fueled by vascular endothelial growth factor (VEGF) signaling, and blockade of this pathway is associated with rapid radiographic response as shown by investigations involving bevacizumab, a humanized monoclonal antibody that targets vascular endothelial growth factor A (VEGF-A), and cediranib, a pan-VEGF receptor tyrosine kinase inhibitor. 5 -7 Bevacizumab has received accelerated regulatory approval for use as salvage chemotherapy against recurrent GBM in the US and appears to prolong progression free survival and reducing symptom burden, though improvement in overall survival has not been effectively demonstrated. 5, 7 However, bevacizumab has not universally received approval (for instance, in Europe) for use in recurrent glioblastoma due to the absence of survival benefit from a randomized controlled trial. 8 Recently completed phase III clinical trials using bevacizumab in newly diagnosed glioblastoma patients have also shown improvement in PFS but failed to reveal a significant benefit to overall survival. 9, 10 Glioblastomas that progress during bevacizumab therapy tend to be unresponsive to additional therapy. 11 -13 Even with a second bevacizumab containing regimen, response is poor with retrospective studies showing a PFS-6 of ,2%. 12, 13 Without effective salvage therapy, improvement in survival for these patients may lie in optimizing the initial bevacizumab exposure.
Current dosing strategies of bevacizumab for glioma are largely based on the initial experience in patients with other malignancies and subsequent data from prospective trials validating its use in recurrent GBM population. 14, 15 The optimal duration of bevacizumab therapy has not been established which in turn has led to varied practice patterns including indefinitely prolonged therapy or discontinuation after an arbitrary time period. In addition, if disease progression is seen while on bevacizumab treatment, treatment is often continued with additional agents to avoid the possibility of rebound tumor progression 16 However, indefinite treatment also increases the risk of rare but life threatening side-effects of bevacizumab. Optimal treatment with bevacizumab requires identifying an appropriate duration of treatment that maximizes benefit but also avoids the risks of prolonged therapy by safe discontinuation. This has been difficult to study given the concern that arbitrary discontinuation would result in rapid rebound tumor progression. However, a subset of patients who respond to bevacizumab have treatment discontinuation for reasons other than disease progression providing an opportunity to address this question. In this study, we examined the characteristics and outcomes of this subset, including determining the incidence of tumor rebound and characterizing their patterns of recurrence and response to salvage chemotherapy.
Patients and Methods

Patients
The neuro-oncology longitudinal database at the University of Texas MD Anderson Cancer Center was queried for patients with glioblastoma treated with bevacizumab, using a HIPAA compliant protocol approved with waiver of consent by the institutional review board. From 2005 -2011, there were 342 patients with glioblastoma treated with a bevacizumab containing regimen. For further analysis consistent with the objective of the study, we included only patients with durable disease control with bevacizumab defined as those who received at least 6 months of therapy. Next we separated the cohort into two groupspatients who had bevacizumab discontinued for reasons other than disease progression (Bev-D) (including toxicity, patient decision or completion of a planned period of treatment) and patients who continued on therapy with bevacizumab (Bev-S), dosed at 10 mg/kg every 2 weeks on 28 day cycles, until progression. Clinical characteristics and outcomes of these two groups were reviewed. Radiographic progression was scored according to changes seen on MRI based on RANO criteria, and patterns of progression were evaluated based criteria proposed by Pope et al., and described as local, distant, diffuse, or multifocal.
17,18
Statistical Methods
Overall survival (OS) and progression free survival (PFS) were computed using the Kaplan-Meier method and the significance of differences between groups was calculated using a log-rank analysis. Patients were censored at the time of their last follow up if no event was recorded. PFS was calculated from initiation of therapy to progression or death. Time to next progression was defined as the time from date of progression after bevacizumab therapy to the date of progression on the next salvage therapy. Patterns of failure were compared using a generalized Fisher exact test. Standard end points of PFS at 12, median PFS, and median OS were determined. For the Bev-D subset, PFS was determined from initiation of bevacizumab to disease progression in all but two patients, given that no additional treatment was given after bevacizumab discontinuation. In the two patients who received isotretinoin before documented disease progression, PFS was calculated from bevacizumab initiation to initiation of isotretinoin to account for the possibility that isotretinoin might have prolonged time to progression.
In a conventional analysis, the event of interest is used as a baseline covariate to compare the outcomes of treatment. However, in the case of bevacizumab discontinuation, since the reason for discontinuation was not known until the cessation of treatment, this parameter could not be used as a baseline covariate to compare PFS or OS curves on bevacizumab therapy. Instead, evaluation of the effect of bevacizumab discontinuation was made using the hazard function. To do so, this was treated as a three-state problem, with all patients starting in the "initial state" of bevacizumab treatment ( Figure 1 ). As follow-up proceeded, patients could transition from this initial state into one of two additional states: "discontinuation" or "progression". Finally, patients could transition from the discontinuation state to the progression state.
To assess the effect of bevacizumab discontinuation on PFS, the overall PFS hazard rates for the initial state and the discontinuation state were estimated. In this study, discontinuation was time-dependent covariate and not a baseline one. In computing the PFS hazard rate for the initial state, patients were censored when they transitioned into the discontinuation state. For computing the PFS hazard rate for the discontinuation state, left truncation (or delayed entry) was permitted. This refers to the fact that usually all patients are in the risk set for progression at time zero when the PFS measurement begins; however in the delayed entry due to discontinuation, a subset of patients enter the risk set after "time zero" because discontinuation occurs after this time point. This is another way to indicate that discontinuation is a time-dependent covariate and not a baseline covariate. Additionally, Cox-regression models were created to investigate the effect of discontinuation on PFS with a univariate analysis using discontinuation as a time-dependent covariate to indicate the irreversible state change from the initial state to the discontinuation state and a multivariate analysis using age, total resection, number of prior therapies, KPS, and discontinuation.The models were also used to determine the hazard ratio of discontinuation which refers to the PFS hazard rate for the discontinuation state divided by the PFS hazard rate for the initial state.
Salvage therapy was defined as treatment initiated after disease progression in both the Bev-D and Bev-S groups. Time to next progression was defined as the period between initial Fig. 1 . Analysis of the rates of progression using a three state model: Patients start in the "initial state," representing initiation of bevacizumab treatment. Patients transition from this initial state into either "discontinuation" or "progression" states. Finally, patients transition from the discontinuation state to the progression state.
Anderson et al.: Bevacizumab discontinuation in recurrent glioblastoma progression after bevacizumab treatment and the next progression on salvage therapy. For the two patients in the Bev-D arm who receive isotretinoin prior to progression, time to next progression was measured from the time of treatment failure on isotretinoin therapy.
Results
Patient characteristics and Treatment
Of the 342 patients with glioblastoma treated with bevacizumabcontaining regimens identified retrospectively from our database, 82 patients qualified for further analysis based on our selection criteria (adults with recurrent glioblastoma and at least 6 months of bevacizumab treatment without progression); of these 18 were Bev-D patients and 64 Bev-S ( Table 1 ). The two cohorts were otherwise similar in characteristics, such as age, gender, ethnicity, KPS, and extent of resection. Seventeen of 18 Bev-D patients and 52 of the 64 Bev-S patients received bevacizumab at 1 st or 2 nd relapse. The patterns of bevacizumab use in Bev-D patients and Bev-S patients were similar, with most patients receiving bevacizumab and irinotecan (Table 2 ). Of the patients that discontinued bevacizumab, 4 stopped bevacizumab at a planned end to the course of treatment, which occurred approximately after a year of bevacizumab therapy and the remaining 14 due to an adverse event or toxicity. These events included an intercurrent pancreatitis, a myocardial infarction, an intracerebral hemorrhage, nephrotic syndrome, hypertension, thrombocytopenia, intolerance, and fatigue (Supplementary Table) .
Clinical Outcome
Overall, for the 82 evaluable patients, PFS -12 was 41% (95% CI, 32% -54%) and median PFS was 47 weeks (95% CI, 42-57); the OS-12 was 73% (95% CI, 64% -83%) and median OS was 74 weeks (95% CI, 64-89), from the time of bevacizumab initiation. Bev-D and Bev-S patients had no significant difference in the length of bevacizumab use prior to the next progression, but there was a trend to longer use for Bev-D patients. In the Bev-D patients, the median PFS after discontinuation of the bevacizumab was 27 weeks (95% CI, 15, not reached) and the PFS at 26 weeks (PFS-26) (from time of discontinuation) was 61% (95% CI, 42% -88%). (Table 3) .
We used the hazard function to determine the effect of bevacizumab discontinuation on PFS. Using this method of calculation of the hazard rates, all patients start in the initial state. The 18 Bev-D patients transition from the initial state to the "discontinuation" state and 62/64 Bev-S patients directly transition from the initial state to the "progression" state ( Figure 1 ). There were a total of 4665 person weeks of follow-up obtained in the initial state. With the 62 events, the overall hazard rate was 0.013 (95% CI: 0.010, 0.017). Among the 18 patients that transitioned to the "discontinuation" state, there were a total of 996 person weeks of follow-up obtained after the transition. With 14 of the 18 patients progressing in the "discontinuation" state, the overall hazard rate was 0.014 (95% CI: 0.007, 0.021).
In the Cox regression models used to investigate the effect of discontinuation on PFS, a univariate analysis using the time to discontinuation as a time-varying covariate yielded an unadjusted hazard ratio of discontinuation on PFS of 1.01 (95% CI: 0.53, 1.94, P ¼ 0.98). When all factors of interest: age, extent of resection, number of prior therapies (1 vs. .1), KPS (.85 vs. , ¼ 85), Abbreviations: Bev-D, patients for whom bevacizumab is discontinued prior to disease progression; Bev-S, patients for whom bevacizumab is continued indefinitely or until progression; KPS, Karnofsky Performance Scale. 
Subsequent Progression
In the 14 Bev-D patients with tumor recurrence, the pattern of progression was predominately local disease, followed by diffuse progression and distant failure. 16 In contrast, of the 61 Bev-S patients with radiographic progression, the pattern of progression was predominately diffuse, followed by local disease, distant, and multifocal failure (Table 4 , Supplementary Figure) . These differences in patterns of disease progression between Bev-D and Bev-S patients were statistically significant (P ¼ .079), especially when distant failure and multifocal failure were combined (P ¼ .036).
Ten of the 14 Bev-D patients had disease progression by the time of analysis and had received additional salvage therapy. This yielded a PFS-26 of 47% (95% CI, 23% -94%) with a median PFS of 23 weeks (95% CI, 12, not reached). Six of the patients received re-challenge with bevacizumab therapy in salvage (time to re-challenge ranged from 9.6 weeks to 33 weeks, median 21 weeks), two received isotretinoin, one received a re-challenge with temozolomide and another received stereotactic radiosurgery. Thirty-seven out of 62 Bev-S patients received salvage chemotherapy at progression, with a PFS-26 of 5% (95% CI, 1%-21%) and a median PFS of 9 weeks (95% CI, 6 -11). The difference between the PFS Kaplan Meier plots for the two groups was significant (P ¼ .0007; Figure 2) . Seventeen of the patients received a bevacizumab based regimen, nine received various experimental protocols, and an additional seven received a cytotoxic regimen with temozolomide, CCNU, or carboplatin. One patient received isotretinoin alone and 3 underwent repeat radiation treatment, one of whom received additional bevacizumab.
Discussion
The optimal duration of treatment with bevacizumab for patients with recurrent glioblastoma remains uncertain. 19, 20 In particular, clinical decisions regarding discontinuation of bevacizumab therapy in patients who have stable disease on this agent may arise either due to adverse events during treatment or as a planned decision to minimize risks of indefinite therapy. However, such decision are challenging due to concerns about rapid rebound tumor growth. The focus of this study was to assess whether bevacizumab discontinuation has short term and long term impact on tumor progression and salvage therapy. Given that prospective data are scarce in this setting, this paradigm was examined in a small group of patients in whom bevacizumab was discontinued after at least 6 months of therapy due to adverse events or as a planned decision. The characteristics of such patients (Bev-D) are described in combination with a concurrent group of patients who continued bevacizumab until disease progression (Bev-S).
A novel method to analyze this complex data is highlighted, which involves transitions from an initial state at start of treatment through a discontinuation state and finally to a progression state, with bevacizumab discontinuation treated as a timedependent covariate and the hazard function for progression estimated in a Cox proportional hazards model. In this model, we aimed to estimate the hazard of transitioning from the 
*Local: focus of enhancement or nonenhancing tumor at or within 3 cm of the primary site resection cavity. If tumor extends beyond 3 cm, then it must be mostly or all well-defined. Diffuse: a recurrence either centered or extending more than 3 cm from the primary site or margin of resection cavity with 50% or greater of the margin of the recurrent tumor qualitatively assessed as poorly defined. If any lesion met the definition of diffuse, the pattern at recurrence was categorized as diffuse. Distant: Single new focus of enhancement or a qualitative assessment of recurrence centered more than 3 cm from the primary site resection cavity or margin of the primary residual tumor, which is mostly or all well-defined. Multifocal: more than one lesion site with each lesion having a mostly or completely well-defined border with intervening areas of normal brain signal. Anderson et al.: Bevacizumab discontinuation in recurrent glioblastoma discontinuation state to the progression/death state as assessed from the beginning of the initial state (as opposed to the beginning of the discontinuation state) which was achieved by treating the data as left truncated. This was subsequently compared to the hazard of transitioning from the initial state to the progression/death state (where patients are censored when and if they transitioned to the discontinuation state). This involved the two hazard functions being compared when discontinuation was treated as a time-dependent covariate. The Bev-D and Bev-S patient groups had similar clinical characteristics and treatment with similar bevacizumab containing regimens. The KPS in the Bev-D patients was slightly better at initiation of bevacizumab and at progression than in the Bev-S patients. This may in part be because the latter were more heavily-pretreated treated prior to bevacizumab, with a higher proportion of patients with .2 tumor progressions before bevacizumab therapy. On the other hand, Bev-S patients had a slightly better response to salvage chemotherapy than usually reported after bevacizumab failure. 12 This could however be due to the bias caused by our selecting patients who remained stable for at least 6 months on bevacizumab which may select a group also more sensitive to salvage therapy after bevacizumab failure.
The specter of rebound tumor progression in patients discontinuing bevacizumab is a major concern, as it may involve a dramatic increase in the area of radiographic enhancement after only about 6 weeks from bevacizumab discontinuation and can be associated with rapid clinical decline as measured by KPS and a shortened median OS. 16 Among the Bev-D patients in this study, the median time to tumor recurrence was 27 weeks, suggesting that discontinuation for reasons other than progression is not associated with rebound tumor growth.
Bevacizumab discontinuation is a clinical variable which becomes known only after the course of treatment; hence, a retrospective analysis can introduce bias in comparison of PFS and OS between the Bev-S and Bev-D groups. To address this, a three-state model was utilized and the hazard function for progression estimated to compare the two groups. The PFS hazard rates from this analysis for the Bev-D and Bev-S patients were found to be similar; this result suggests that discontinuation was not associated with early tumor progression. Additional analysis with Cox-regression models using discontinuation as a timedependent covariate was performed to complement the hazard function analysis. While the wide confidence intervals of the hazard ratios calculated by the Cox regression models for bevacizumab discontinuation make it difficult to conclusively state the effect of discontinuation on PFS, there was not a strong deleterious effect observed, which also supports a lack of early tumor progression.
Bev-D patients had a better response in terms of PFS and OS to subsequent salvage therapy compared to Bev-S patients, which included patients being re-challenged with bevacizumab. Possibly, tumor recurrence in the Bev-S group occurs due to development of bevacizumab resistance during ongoing therapy whereas in the Bev-D patients, discontinuation of bevacizumab may eventually lead to reestablishment of angiogenesis leading to disease recurrence but without loss of sensitivity to bevacizumab. Our results are similar to that reported in a smaller study evaluating 5 patients with bevacizumab discontinuation which also showed a similar lack of rebound tumor progression and responsiveness to rechallenge with bevacizumab. 21 A difference in the pattern of disease progression was observed between the Bev-D and Bev-S patients, with fewer instances of diffuse progression and more local progression in the Bev-D group. Although the baseline pattern of disease prior to bevacizumab was not evaluated, prior studies evaluating patterns of disease do not suggest that bevacizumab changes patterns of disease progression. 16 Therefore this highlights the fact that the two groups may have an underlying difference in the biological behavior of the tumor which in turn leads to imaging characteristics that influenced discontinuation of bevacizumab in the Bev-D group.
Our study has several limitations; the retrospective nature of the review introduces inherent selection bias related to the patient population and outcome criteria. As these patients were stable on bevacizumab treatment for at least 6 months, the patient group in this study does not represent the general population of patients with recurrent glioblastoma. Additionally, the Bev-D group is small, representing only about 5% of the recurrent glioblastoma patients receiving bevacizumab, introducing potential selection bias and limiting the power of our conclusions. Although there was variability in the initial bevacizumab-containing regimens and in the therapies for subsequent disease progression chosen at the discretion of the treating physician, these factors were unlikely to influence outcome given that combination therapy with bevacizumab at initial treatment or after failure of single agent bevacizumab has not been reported to significantly change clinical outcome. 5, 15 The timing of treatment with bevacizumab was also variable, with Bev-S patients tending to be more heavily pretreated, but there was no significant difference in the lengths of time from diagnosis to bevacizumab initiation.
Despite these limitations, this study addresses important questions regarding the use of bevacizumab particularly when a decision to discontinue treatment has to be made in the setting of stable disease. The results of our study suggest that discontinuation of therapy in patients who are stable on bevacizumab therapy does not seem to result in rebound tumor growth and that re-challenge with bevacizumab after cessation for reasons other than progression is feasible. These results warrant prospective studies to define the optimal duration of bevacizumab therapy and the impact of discontinuation of treatment when necessary. In this context, data from the phase III clinical trials, RTOG 0825 and AVAglio, using bevacizumab in newly diagnosed glioblastoma may provide insights into issues with bevacizumab discontinuation in earlier stages of the disease.
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